Herpes Information Home  • Contact Us

Condylox Research Studies

Induction chemoradiotherapy for advanced stage III non-small cell lung cancer: long-term follow-up in 42 patients.
Release of mitochondrial cytochrome c is upstream of caspase activation in chemical-induced apoptosis in human monocytic tumour cells.
A feasibility study of continuous etoposide infusion combined with thoracic radiation for non-small cell lung cancer.
High-dose chemotherapy in germ cell tumours: a large single centre experience.
Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer.
Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
Metastable polymorph of etoposide with higher dissolution rate.
[A case of metastatic testicular tumor in a schizophrenic patient: experience of multidisciplinary treatment at the urology ward]
[Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation]
1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage.
Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy.
Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer.
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Advanced non-small-cell lung cancer: adjunctive interferon gamma in induction and maintenance therapy.
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer.
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
Monocyte chemoattractant protein-1 gene modification of multidrug-resistant human lung cancer enhances antimetastatic effect of therapy with anti-P-glycoprotein antibody in SCID mice.
p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells.
Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis.
Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage.
[Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?]
A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma.
Monitoring of chemotherapy-induced proteinuria using capillary zone electrophoresis.
Hypersensitivity to carboplatin in children.
Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.
[Oral antitumor drugs for hematological malignancies]
[Progress in oral anti-cancer drug therapy for urological cancer]
Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions.
Testicular cancer: an oncological success story.
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society.
A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin's disease.
Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK).
Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors.
CD4/CD8 double-positive adult T cell leukemia with preceding cytomegaloviral gastroenterocolitis.
Etoposide enhances the lethal effect of radiation on breast cancer cells with less damage to mammary gland cells.
Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients.
ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
[Association of celiac disease and esophageal small cell carcinoma]
Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs.
Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cells.
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
Physical and chemical stability of etoposide phosphate solutions.
[Sinus histiocytosis (Destombes-Rosai-Dorfman disease) revealed by extranodal spinal involvement]
Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.
Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Flow cytometric detection of p53 protein after incubation of a pre-B cell line with antitumor agents.
[Sensitivity to etoposide of human malignant glioma cell lines. Mechanisms of action]
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis.
Germ cell tumour of testis.
Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
Failure of high-dose chemotherapy with peripheral blood stem cell support for refractory placental site trophoblastic tumor.
Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma.
Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells.
Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
[Diagnostic and therapeutic concepts of HPV infection in HIV-positive women]
Extraskeletal Ewing's sarcoma.
Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
Treatment outcome of patients with brain metastases from malignant germ cell tumors.
Expression of HSP27 results in increased sensitivity to tumor necrosis factor, etoposide, and H2O2 in an oxidative stress-resistant cell line.
Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Transcriptional activation of the human S100A2 promoter by wild-type p53.
Identification of the genes responsive to etoposide-induced apoptosis: application of DNA chip technology.
Effect of intracarotid infusion of etoposide: modification of the permeability of the blood-brain barrier and the blood-tumor barrier in rat brain tumor model.
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
[Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity]
[Nedaplatin and etoposide combination chemotherapy in a patient with small cell carcinoma undergoing hemodialysis]
[Successful combination chemotherapy for a case of small cell carcinoma of the rectum with multiple liver metastasis]
Preirradiation evaluation and technical assessment of involved-field radiotherapy using computed tomographic (CT) simulation and neoadjuvant chemotherapy for intracranial germinoma.
Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
Gestational trophoblastic disease: does central nervous system chemoprophylaxis have a role?
Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model.
High incidence of treatment failure with vincristine, etoposide, epirubicin, and prednisolone chemotherapy with successful salvage in childhood Hodgkin disease.
Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer.
Correlation of tubulin-binding and antitumor activities of podophyllotoxin analogs.
Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer.
Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.
Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
The presentation and management of post-partum choriocarcinoma.
Inhibition of caspases inhibits the release of apoptotic bodies: Bcl-2 inhibits the initiation of formation of apoptotic bodies in chemotherapeutic agent-induced apoptosis.
Early detection by ultrasound scan of severe post-chemotherapy gut complications in patients with acute leukemia.
Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Paclitaxel in the treatment of hormone-refractory prostate cancer.
The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission.
Rapid progression of squamous cell carcinoma of the cervix after hyperbaric oxygenation.
Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Cytotoxicity of 2-chlorodeoxadenosine (cladribine, 2-cdA) in combination with other chemotherapy drugs against two lymphoma cell lines.
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate.
Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis.
Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction.
Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome.
Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents.
Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
Oral etoposide for patients with metastatic gastric adenocarcinoma.
Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death.
Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance.
Comparative effects of Bcl-2 over-expression and ZVAD.FMK treatment on dexamethasone and VP16-induced apoptosis in CEM cells.
Cell death in the avian blastoderm: resistance to stress-induced apoptosis and expression of anti-apoptotic genes.
The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Differential involvement of DNases in HeLa cell apoptosis induced by etoposide and long term-culture.
Activation of a low pH-dependent nuclease by apoptotic agents.
Benzodiazepine receptor agonists modulate thymocyte apoptosis through reduction of the mitochondrial transmembrane potential.
Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II.
Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
cdc25A is necessary but not sufficient for optimal c-myc-induced apoptosis and cell proliferation of vascular smooth muscle cells.
Apoptosis of unstimulated human lymphocytes and DNA strand breaks induced by the topoisomerase II inhibitor etoposide (VP-16).
Intracranial germ cell tumors in children with and without Down syndrome.
Successful therapy in a child with a congenital peripheral medulloepithelioma and disruption of hindquarter development.
Transcriptional activation of the human glutathione peroxidase promoter by p53.
Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer.
Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group.
Enhanced sensitivity of small cell lung cancer cell lines to cisplatin and etoposide after infection with adeno-associated virus type 2.
[Continuous radiosensitizing chemotherapy]
Role of MRP1 in multidrug resistance in acute myeloid leukemia.
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction.
High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
Pilot study on induction chemotherapy with cisplatin, epirubicin, etoposide and bleomycin in cervical cancer stage Ib, IIa and IIb.
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.
Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer.
Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1.
Comparison of effects of natural or artificial rodent diet on etoposide absorption in rats.
Release of adenylate kinase 2 from the mitochondrial intermembrane space during apoptosis.
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients.
T-cell-rich B-cell non-Hodgkin's lymphoma mimicking Hodgkin's disease.
Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.
The inv(11)(p15q22) chromosome translocation of therapy-related myelodysplasia with NUP98-DDX10 and DDX10-NUP98 fusion transcripts.
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer.
In vitro toxicity of taxol based anticancer drug combinations on human hemopoietic progenitors.
Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2.
Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis.
Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL.
[Combination chemotherapy--present status and problems]
[The role of mitochondria in apoptosis in U937 and Molt-4 cells: difference in order of mitochondrial membrane potential (delta psi m) reduction and interleukin-1 beta-converting enzyme (ICE) on signal transduction pathway in each cell type]
[A case report: modified PMUE therapy might be effective for advanced gastric carcinoma with pulmonary carcinomatous lymphangitis]
[A giant invasive thymoma made resectable by cisplatin + vincristine + doxorubicin + etoposide (CODE)]
[A case of leukemic lymphoma complicated by M-proteinemia: effectiveness of long-term daily administration of oral low-dose etoposide in continuing remission]
Brain colchicine-binding protein (tubulin) during postnatal development in the rat.
Effects of the epipodophyllotoxin derivative VM 26 in mitosis and in interphase.
Caspase-dependent proteolysis of integral and peripheral proteins of nuclear membranes and nuclear pore complex proteins during apoptosis.
Cytoplasmic acidification is not an effector mechanism of VP16 or DEX-induced apoptosis in CEM T leukaemia cells.
Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation.
[Chemotherapy of testicular cancer]
Extracellular matrix inhibits apoptosis and enhances endothelial cell differentiation by a NfkappaB-dependent mechanism.
Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma.
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Podophyllotoxin in serum: absorption subsequent to three-day repeated applications of a 0.5% ethanolic preparation on condylomata acuminata.
Pharmacokinetics of etoposide and carboplatin in cerebrospinal fluid and plasma during hyperosmotic disruption of the blood brain barrier and intraarterial combination chemotherapy.
Germ cell cancer.
Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.
[Two cases of giant testicular tumor with widespread extension to the spermatic cord: usefulness of upfront chemotherapy]
Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation.
CombiTool--a new computer program for analyzing combination experiments with biologically active agents.
Myeloid malignancies induced by alkylating agents in Nf1 mice.
Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells.
[High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996]
Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients.
Etoposide phosphate: new preparation. Makes outpatient therapy easier.
The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts.
Cell cycle dependent subcellular distribution of Cdc25B subtypes.
Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.
Plasma membrane potential in thymocyte apoptosis.
BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG)
Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.
Chemopreventive effect of 4'-demethyl epipodophyllotoxin on DMBA/TPA-induced mouse skin carcinogenesis.
Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation.
MRP3, an organic anion transporter able to transport anti-cancer drugs.
Molluscum Contagiosum.
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Hypophyseal non-Hodgkin's lymphoma presenting with diabetes insipidus: a case report.
Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors.
Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer.
The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines.
Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM).
Pharmacokinetics of etoposide after intrathoracic instillation to lung cancer patients with pleural effusion.
Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuroblastoma cells by modulating nuclear import of p53.
Severe muscle weakness due to hypokalemia as a manifestation of small-cell carcinoma.
Mitochondrial changes during the apoptotic process of HeLa cells exposed to cisplatin.
Cutaneous granulocytic sarcoma mimicking immunoblastic large cell lymphoma.
Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide.
Schedule-dependent efficiency of thermochemotherapy in vitro with etoposide and heating at 43 degrees C.
Use of CDC2 from etoposide-treated cells as substrate to assay CDC25 phosphatase activity.
The influence of radiation and chemotherapy-related DNA strand breaks on carcinogenesis: an evaluation.
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Induction of gamma-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients.
A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer: a phase II study.
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo.
Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis.
Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts.
Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells.
Clinical assessment of EMA/CO induced DNA damage in peripheral blood lymphocytes of high-risk gestational trophoblastic tumor patients.
Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts.
Low levels of p53 are associated with resistance to tetrachlorodibenzo-p-dioxin toxicity in DBA/2 mice.
Immortalization and characterization of Nijmegen Breakage syndrome fibroblasts.
[Primary lymphoma of the thyroid with contralateral recurrence--case report]
Small cell carcinoma of the cervix complicated by pregnancy.
Avascular necrosis in patients treated with BEP chemotherapy for testicular tumours.
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.
Retroperitoneal germ cell tumor treated by PVeBV chemotherapy: a case report.
Developmental toxicity of the topoisomerase inhibitor, etoposide, in rabbits after intravenous administration.
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells.
Etoposide-induced activation of c-jun N-terminal kinase (JNK) correlates with drug-induced apoptosis in salivary gland acinar cells.
Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases.
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
Protein kinase C delta is essential for etoposide-induced apoptosis in salivary gland acinar cells.
Influence of etoposide on the retention of radiolabeled low-density lipoprotein in the arterial wall.
Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study.
Phosphate release during microtubule assembly: what stabilizes growing microtubules?
Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells.
Oxidative stress inhibits apoptosis in human lymphoma cells.
DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development.
Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer.
Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Changes in lymphocyte number during cancer chemotherapy and their relation to clinical response.
A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
Distinct mechanisms underlay DNA disintegration during apoptosis induced by genotoxic and nongenotoxic agents in neuroblastoma cells.
The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity.
Short-term chemotherapy and palliative radiotherapy for elderly patients with stage IV non-small cell lung cancer: a phase II study.
Neuron-specific enolase, thymidine kinase, and tissue polypeptide-specific antigen in diagnosis and response to chemotherapy of small-cell lung cancer.
Imaging of caspase-3 activation in HeLa cells stimulated with etoposide using a novel fluorescent probe.
Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection.
[Persistent Lactobacillus casei subspecies rhamnosus bacteremia in a 14 year old girl with acute myeloid leukemia. A case report]
[Colony stimulating factors in polychemotherapy of testicular tumors. A comparison between G-CSF and GM-CSF]
125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer.
[A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate]
[Pleiotropic changes in karyotype structure of Chinese hamster fibroblast cell lint CHL V-79 RJK in relation to their acquisition of resistance to etoposide, an inducer of apoptosis]
Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF.
Preliminary observations for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma. Report of five cases.
New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models.
Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin.
Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxyacridone.
Quantitative measurement of mammalian chromosome mitotic loss rates using the green fluorescent protein.
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
ESHAP is an active regimen for relapsing Hodgkin's disease.
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report.
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Anticancer drug design based on plant-derived natural products.
[Intensive chemotherapy in the treatment of patients with metastatic breast cancer]
Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1.
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion.
Oral etoposide for patients with advanced adenocarcinoma of the pancreas.
Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives.
Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39.
Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile.
[Current therapeutic orientation toward testicular germ cell tumors]
Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
Pharmacological analysis of etoposide in elderly patients with lung cancer.
High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma.
Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein.
Primary small cell carcinoma of the esophagus with achalasia in a patient in whom pro-gastrin-releasing peptide and neuron-specific enolase levels reflected the clinical course during chemotherapy.
Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide.
Type IV collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis via beta(1) integrin-mediated survival signals.
Redistribution of cytochrome c precedes the caspase-dependent formation of ultracondensed mitochondria, with a reduced inner membrane potential, in apoptotic monocytes.
Cancer-associated retinopathy during treatment for small-cell lung carcinoma.
Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
Effects of spin labeled derivatives of podophyllotoxin on cell cycle and macromolecular synthesis in human lymphoid leukemia Molt 4B cells.
Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome.
Dose-intensive chemotherapy for breast cancer with brain metastases: a case series.
The role of chemotherapy in intracranial germinoma: a case report.
[Two-step ultra high-dose chemotherapy with peripheral blood stem cell autotransplantation for refractory testicular cancer: a case report]
Involvement of caspase 3-activated DNase in internucleosomal DNA cleavage induced by diverse apoptotic stimuli.
A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.
Is surveillance for stage 1 germ cell tumours of the testis appropriate outside a specialist centre?
Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells.
In vitro cytotoxicity of salvicine, a novel diterpenoid quinone.
Phase II study of a radiotherapy/etoposide combination for patients with newly malignant gliomas.
Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide.
Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation.
NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis.
Cleavage and inactivation of ATM during apoptosis.
Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2).
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
Marked increase in plasma ACTH with tumor reduction after chemotherapy in ectopic ACTH syndrome.
Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis.
Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach.
Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin.
Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus.
Protein tyrosine kinase Lyn mediates apoptosis induced by topoisomerase II inhibitors in DT40 cells.
9-Deoxopodophyllotoxin derivatives as anti-cancer agents.
[Combined treatment with CDDP and radiation effective against neuroendocrine carcinoma of the urinary bladder: a case report]
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
A case of hemophagocytic lymphohistiocytosis with prolonged remission after syngeneic bone marrow transplantation.
Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis.
Effects of docetaxel on the in vitro growth of human myeloid progenitors.
Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group.
Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
Evaluation of chemotherapy response in patients with small cell lung cancer using Technetium-99m-tetrofosmin.
[Prognosis, treatment completion, and complications in nonresponders in the study AML-BFM87]
[High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS]
Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94.
Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7.
Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells.
An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature.
The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Comparative in vitro and in vivo assessment of genotoxic effects of etoposide and chlorothalonil by the comet assay.
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
Drug delivery of anticancer agents: water soluble 4-poly (ethylene glycol) derivatives of the lignan, podophyllotoxin.
[Evaluation of antitumor activity of etoposide administered orally for 21 consecutive days against human uterine cancer subcutaneous and/or orthotopic xenografts in nude mice]
[Usefulness of combination therapy with expandable metallic stent replacement and FLEP chemotherapy (consisting of 5-FU, leucovorin, etoposide and cisplatin) for advanced esophageal cancer invading the bronchus: a case report]
[Results of clinical trials in the treatment of acute myeloid leukemia in adults during a 7-year period]
Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy.
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
[The value of intracellular CD41 antigen detection to the diagnosis of acute megakaryoblastic leukemia]
[Atypical paraneoplastic myasthenic syndrome: Lambert-Eaton syndrome or myasthenia?]
Aggressive form of pleural epithelioid haemangioendothelioma: complete response after chemotherapy.
Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity.
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.
Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma.
The effects of two different cisplatin-based chemotherapy regimens on advanced non-small cell lung cancer.
Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells.
[Mechanisms of drug resistance of two cell lines of human chronic promyelocytic leukemia K562, resistant to DNA topoisomerase II inhibitors adriamycin and etoposide]
Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.
The endoplasmic reticulum chaperone glycoprotein GRP94 with Ca(2+)-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis.
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
[Burkitt's lymphoma--a case report]
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia.
Inhibition of FAS/FAS-ligand does not block chemotherapy-induced apoptosis in drug sensitive and resistant cells.
Effects of PARP inhibition on drug and Fas-induced apoptosis in leukaemic cells.
Pharmacokinetics of anticancer drugs in vitro.
In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML.
Effects of CSFS and their combinations with chemotherapeutic agents (CH) on leukemic blasts (LB) in children (MTT-assay).
Modulation of apoptosis and enhancement of chemosensitivity by decreasing cellular thiols in a mouse B-cell lymphoma cell line that overexpresses bcl-2.
Bcl-2 expression correlates with apoptosis induction but not tumor growth delay in transplantable murine lymphomas treated with different chemotherapy drugs.
Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU.
Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells.
Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months.
Oral etoposide for refractory and relapsed neuroblastoma.
Acute myelogenous leukemia after treatment for malignant germ cell tumors in children.
The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Salvage chemotherapy with IAPVP-16 for advanced refractory or relapsed follicular lymphomas.
Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer.
Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): a randomized trial.
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group.
Comparative analysis of different methodological approaches to the in vitro study of drug-induced apoptosis.
[First-line chemo-radiotherapy neoadjuvant treatment in locally advanced (T4) epidermoid carcinoma of the esophagus]
Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies.
Autologous bone marrow transplantation in non-Hodgkin's lymphoma patients: effect of a brief course of G-CSF on harvest and recovery.
Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Macrostatin, a novel macromolecular inhibitor of topoisomerases produced by Streptomyces avermitilis no. C-127.
Yeast topoisomerase II is inhibited by etoposide after hydrolyzing the first ATP and before releasing the second ADP.
The frequency of illegitimate TCRbeta/gamma gene recombination in human lymphocytes: influence of age, environmental exposure and cytostatic treatment, and correlation with frequencies of t(14;18) and hprt mutation.
Intracellular S-glutathionyl adducts in murine lung and human bronchoepithelial cells after exposure to diisocyanatotoluene.
Superoxide anion inhibits drug-induced tumor cell death.
Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.
Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen.
Insulin receptor substrate-4 enhances insulin-like growth factor-I-induced cell proliferation.
ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide.
Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro.
Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.
Volumetric reduction of a choroid plexus carcinoma using preoperative chemotherapy.
Inhibition by 4'-demethyl-epipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle.
Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
Inhibitors of topoisomerase II as pH-dependent modulators of etoposide-mediated cytotoxicity.
Expression and release of chemokines associated with apoptotic cell death in human promonocytic U937 cells and peripheral blood mononuclear cells.
[A case of extragonadal germ cell tumor with inferior vena caval tumor thrombus]
[Small cell neuroendocrine carcinoma of the urinary bladder: a case report]
HSP27 inhibits cytochrome c-dependent activation of procaspase-9.
[Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia]
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer.
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
Combined chemoradiation therapy for limited-stage small-cell lung cancer.
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.
In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii.
Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Apoptotic cytosol facilitates Bax translocation to mitochondria that involves cytosolic factor regulated by Bcl-2.
Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
[A case of metastatic nephroblastoma in an adult with favorable outcome under cisplatyl, etoposide]
Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP).
Protection from cell death by mcl-1 is mediated by membrane hyperpolarization induced by K(+) channel activation.
Interleukin-15 is a potent survival factor in the prevention of spontaneous but not CD95-induced apoptosis in CD4 and CD8 T lymphocytes of HIV-infected individuals. Correlation with its ability to increase BCL-2 expression.
Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Haem oxygenase-1 prevents cell death by regulating cellular iron.
[Arterial infusion therapy with implantable port for inoperable hepatobiliary tumors]
[Significance and effects of intraperitoneal cisplatin administration for ovarian cancer]
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study.
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
Outcome and reproductive function after chemotherapy for ovarian dysgerminoma.
Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
Diffuse large-cell lymphoma of the testis.
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.
[Combined modality therapy for malignant lymphoma of the primary central nervous system: a preliminary report of a new chemotherapeutic regimen with "PEACE"]
Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT.
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
Etoposide-induced pulmonary toxicity.
DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
Etoposide as a virocidal anticytomegalovirus therapy: intravitreal toxicology and pharmacology in rabbits.
Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clinique de l'Université Catholique de Louvain, Brussels and Liège, Belgium.
Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial.
Overexpression of basic fibroblast growth factor (FGF-2) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells.
Clinical outcome of high-dose chemotherapy combined with peripheral blood stem cell transplantation for male germ cell tumors.
Combined treatment of metastatic osteosarcoma of the spine.
Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.
Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.
Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study.
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation.
Regulation of PTEN expression in neuronal apoptosis.
The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC).
Ifosfamide in non-small-cell lung cancer.
Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma.
[Mechanism of occurrence of secondary tumors by antitumor drugs]
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Efficacy of total androgen blockade in metastatic prostatic carcinoma with transient hypogonadotropic hypogonadism: a case report.
Population pharmacokinetic approach to compare oral and i.v. administration of etoposide.
Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma.
Unusual cervical spinal cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide in conjunction with osmotic blood brain-barrier disruption in the vertebral artery.
A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy.
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL.
Occult pulmonary synovial sarcoma confirmed by molecular techniques.
Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34+ cell collections are not necessarily cost-effective.
[Combined alternating radiochemotherapy in stage III (TNM) (limited disease) small cell bronchial carcinoma: a phase II study with carboplatin/etoposide/vincristine and alternating radiotherapy]
Risk factors for relapse in stage I non-seminomatous germ-cell tumors: preliminary results of the German Multicenter Trial. German Testicular Cancer Study Group.
Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999).
High-dose salvage chemotherapy. Germ-cell tumor treatment results in Germany.
Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
The bacterial cytolethal distending toxin (CDT) triggers a G2 cell cycle checkpoint in mammalian cells without preliminary induction of DNA strand breaks.
BRCA1 signals ARF-dependent stabilization and coactivation of p53.
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Extraskeletal osteosarcoma of the mediastinum after treatment of a mediastinal germ-cell tumor.
Duchenne muscular dystrophy and concomitant metastatic alveolar rhabdomyosarcoma.
Posttranscriptional gene silencing in Neurospora by a RecQ DNA helicase.
Colchicine permeation is required for inhibition of concanavalin A capping in Chinese hamster ovary cells.
CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer.
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study.
Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents.
Biologically active components against Drosophila melanogaster from Podophyllum hexandrum.
The isolation and genetic analysis of V79-derived etoposide sensitive Chinese hamster cell mutants: two new complementation groups of etoposide sensitive mutants.
The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.
Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma.
Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
Proteolytic activation of protein kinase C delta and epsilon by caspase-3 in U937 cells during chemotherapeutic agent-induced apoptosis.
PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway.
Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
Management of small cell lung cancer: current state of the art.
Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors.
Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential.
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma.
Mixed germ cell tumour of the pineal region: a case report.
Mini-ICE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis.
In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
Heat-induced drug resistance is associated with increased expression of Bcl-2 in HL60.
Cytotoxic activity and antiproliferative effects of a new semi-synthetic derivative of Ent-3 beta-hydroxy-13-epi-manoyl oxide on human leukemic cell lines.
Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
Effect of fluconazole on the growth and adhesion of Candida albicans in the presence of antineoplastic agents.
Protection of acute myeloblastic leukemia cells against apoptotic cell death by high glutathione and gamma-glutamylcysteine synthetase levels during etoposide-induced oxidative stress.
Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice.
Effects of G-CSF and high-dose methylprednisolone on peripheral stem cells, serum IL-3 levels and hematological parameters in acute lymphoblastic leukemia patients with neutropenia: a pilot study.
Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
Cancer gene therapy using a pro-apoptotic gene, caspase-3.
[Results of chemotherapy and salvage surgery for advanced testicular cancer]
[Treatment of advanced testicular cancer and toxicity of chemotherapy]
[Clinical study of high-dose chemotherapy with peripheral blood stem cell transplantation for poor-risk germ cell tumor]
[Clinical results of super high-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced germ cell tumor]
[High-dose chemotherapy with peripheral blood stem cell autotransplantation for patients with poor-risk testicular germ cell tumors--pilot study of the Japan Blood Cell Transplantation Study Group]
[Chemically-induced paraneoplastic hyperleukocytic lung]
In vivo antitumor activity and induction of insulin-like growth factor-1-resistant apoptosis by SC-alphaalphadelta9.
[A successfully operated case of choriocarcinoma with recurrent intratumoral hemorrhage]
A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.
A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins.
Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21;q23).
Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Effect of the topoisomerase-II inhibitor etoposide on meiotic recombination in male mice.
Management of small cell lung cancer in elderly.
Mycosis fungoides bullosa simulating pyoderma gangrenosum.
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.
Mediastinal atypical carcinoid and neurofibromatosis type 1.
Tubulin aggregation and disaggregation: mediation by two distinct vinblastine-binding sites.
Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.
[Evidence based chemotherapy for lung cancer]
[A long-term survivor of extensive-stage small cell lung cancer]
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient.
Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease.
Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies.
Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity.
Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study.
Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.
Action of free radical in podophyllic acid piperindyl hydrazone nitroxide radical on its antitumor activity and toxicity.
Expression pattern of chemoresistance-related genes in human malignant brain tumors: a working knowledge for proper selection of anticancer drugs.
VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
[Treatment of 129 patients with advanced and recurrent malignant ovarian germ cell tumor]
Oral etoposide for Merkel cell carcinoma in patients previously treated with intravenous etoposide.
Selective increase in cellular A beta 42 is related to apoptosis but not necrosis.
Degradation of focal adhesion proteins during nocodazole-induced apoptosis in rat-1 cells.
Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer.
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Induction of mitochondrial permeability transition and cytochrome C release in the absence of caspase activation is insufficient for effective apoptosis in human leukemia cells.
[Kinetics of peripheral blood CD34-positive cells and the optimum timing for harvesting peripheral blood stem cells during BEP chemotherapy in patients with testicular germ cell tumor]
Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm.
p53 regulates the expression of the tumor suppressor gene maspin.
Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes.
[Chemotherapy of malignant inoperable gliomas. The association of fotemustine-cisplatine-etoposide as neoadjuvants]
Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma.
Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
Concurrent cisplatin/etoposide chemotherapy plus twice daily thoracic radiotherapy in limited stage small cell lung cancer: a phase II study.
[A case of stage IVb (H2P0N4T4) gastric cancer successfully treated with neoadjuvant chemotherapy (PMFE therapy)]
A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer.
[The treatment of acute myelocytic leukemia during the first recurrence by means of a new cytostatic combination]
A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
The role of mitochondria in apoptosis induced in vitro.
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation.
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.
A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.
Autologous stem cell transplantation for acute myeloid leukemia in first remission.
Apoptosis inhibitory effect of the isothiourea compound, tri-(2-thioureido-S-ethyl)-amine.
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Clinics in diagnostic imaging (44). Testicular tumour with retroperitoneal lymphadenopathy and inferior vena cava thrombosis.
Extrapulmonary small-cell carcinoma: report of three cases and update of therapy and prognosis.
Uncoupling of apoptosis and Jun/AP-1 activity in human promonocytic cells treated with DNA-damaging and stress-inducing agents.
Cyclophosphamide and etoposide for non-small cell and small cell lung cancer.
Current role of oral etoposide in the management of small cell lung cancer.
The role of oral etoposide in non-small cell lung cancer.
Oral etoposide in germ cell tumours.
Oral etoposide in lymphoma.
Oral etoposide for the treatment of recurrent ovarian cancer.
Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues.
Recent developments in oral chemotherapy options for gastric carcinoma.
Caspase-mediated cleavage of p130cas in etoposide-induced apoptotic Rat-1 cells.
Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells.
Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice.
A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.
Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385).
Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells.
The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes.
4-Aza-2,3-dehydro-4-deoxypodophyllotoxins: simple aza-podophyllotoxin analogues possessing potent cytotoxicity.
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
Results of treatment after relapse from high-dose chemotherapy in germ cell tumors.
Enhancing effect of electric stimulation on cytotoxicity of anticancer agents against rat and human glioma cells.
Effects of anti-neoplastic agents on the recovery of bacteria and yeasts in an automated blood culture system.
Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.
Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin.
F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report.
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Is there a best transplant conditioning regimen for acute myeloid leukemia?
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis.
[Treatment results of VIP (etoposide, ifosfamide and cisplatin) chemotherapy as a first-line therapy in metastatic germ cell tumors]
Werner's syndrome lymphoblastoid cells are hypersensitive to topoisomerase II inhibitors in the G2 phase of the cell cycle.
Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro.
Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: a Children's Cancer Group Study, CCG-9881.
Metastatic medulloblastoma in 10-year-old girl treated successfully with chemotherapy without radiotherapy.
[Cytoprotective effect of amifostine in children during induction therapy according to BFM-83: report on cases]
Survival signals within the tumour microenvironment suppress drug-induced apoptosis: lessons learned from B lymphomas.
Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90.
Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx.
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine.
Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia.
Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients.
[Germ cell tumors of the testes: state of the art]
[Long-term results of small cell lung cancer treated by surgery combined with postoperative chemotherapy: a report of 65 patients]
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
Cisplatin containing chemotherapy influences HLA-DR expression on monocytes from cancer patients.
Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1.
The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis.
An adult patient with a mixed germ cell tumor of the spermatic cord.
Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Characterization of human lung cancer cells resistant to 4'-O-demethyl-4beta-(2"-nitro-4"-fluoroanilino)-4-desoxypodophyllotoxin , a unique compound in the epipodophyllotoxin antitumor class.
Anticancer drug-induced apoptosis in human monocytic leukemic cell line U937 requires activation of endonuclease(s).
Doxazosin: a new cytotoxic agent for prostate cancer?
Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide.
Pediatric choroid plexus neoplasms.
Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer.
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma]
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.
Poly (ADP-ribose) polymerase induction is an early signal of apoptosis in human neuroblastoma.
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.
A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.
Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals.
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d'Oncologie Thoracique des Régions Alpines.
RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment.
Inhibitor of apoptosis protein hILP undergoes caspase-mediated cleavage during T lymphocyte apoptosis.
Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells.
Experimental induction of apoptosis by a combination of etoposide and radiation treatment.
Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Enhancement of chemotherapeutic agents induced-apoptosis associated with activation of c-Jun N-terminal kinase 1 and caspase 3 (CPP32) in bax-transfected gastric cancer cells.
Proteasome activation as a critical event of thymocyte apoptosis.
[An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide]
Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines.
A phase II study of combined chemoradiotherapy for limited disease-small-cell lung cancer.
Endocrine effects of the podophyllotoxine derivative drug CPH 82 (Reumacon) in patients with rheumatoid arthritis.
Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells.
Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?
Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy.
Podophyllotoxin aza-analogue, a novel DNA topoisomerase II inhibitor.
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects.
Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility study.
Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.
[Management of non-seminomatous germ cell tumors of the testes]
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Involvement of a small GTP-binding protein (G protein) regulator, small G protein GDP dissociation stimulator, in antiapoptotic cell survival signaling.
Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli.
Expression of E-cadherin reduces bcl-2 expression and increases sensitivity to etoposide-induced apoptosis.
Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation.
The prodomain of caspase-1 enhances Fas-mediated apoptosis through facilitation of caspase-8 activation.
Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).
Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro.
Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation.
Depletion of cellular glutathione by conditions used for the passaging of adherent cultured cells.
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line.
Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.
[Intra-abdominal desmoplastic small round-cell tumors. An entity among peritoneal carcinomatoses in young adults]
Novel "reverse Kahne-type glycosylation": access to O-, N-, and C-linked epipodophyllotoxin conjugates.
[VP-16 and VM-26 plus platinum drugs combined with radiotherapy in the treatment of small cell lung cancer]
Assignment of functional amino acids around the active site of human DNA topoisomerase IIalpha.
A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Detection of VP-16-treated HL-60 cell apoptosis by TUNEL electron microscopy.
Distinct Chk2 activation pathways are triggered by genistein and DNA-damaging agents in human melanoma cells.
The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer.
Nitric oxide inhibits apoptosis via AP-1-dependent CD95L transactivation.
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma.
Enzyme-assisted asymmetric total synthesis of (-)-podophyllotoxin and (-)-picropodophyllin.<